Study of safety, reactogenicity and immunogenicity of GlaxoSmithKline’s (GSK)Respiratory Syncytial Virus (RSV)maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants

Trial Identifier:	209544
Sponsor:	GlaxoSmithKline
Start Date:	November 2019
Primary Completion Date:	July 2020
Study Completion Date:	May 2021
Condition:	Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.